Mirabegron Stada

Mirabegron, the active ingredient in Mirabegron Stada, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the treatment of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. Its distribution network ensures timely delivery and regulatory compliance for each shipment.

Mirabegron is used to manage symptoms of overactive bladder, a condition characterized by involuntary bladder contractions. - Overactive bladder: reduces urgency episodes and increases bladder capacity. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daily voids. - Urge urinary incontinence: helps prevent involuntary leakage.

Mirabegron may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Headache: mild to moderate intensity. - Nasopharyngitis: common cold‑like symptoms. - Urinary retention: difficulty initiating urination. - Dry mouth: reduced salivation. - Constipation: infrequent bowel movements.

Serious or Rare Side Effects: - Severe hypertension: markedly high blood pressure requiring medical attention. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema: swelling of face, lips, or throat. - Acute urinary retention: sudden inability to void. - QT interval prolongation: potential cardiac rhythm disturbance.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: check regularly as mirabegron can increase systolic and diastolic values. - Assess renal function: dose may need adjustment in severe impairment. - Avoid in uncontrolled hypertension: contraindicated due to cardiovascular risk. - Caution in narrow‑angle glaucoma: may exacerbate intra‑ocular pressure. - Pregnancy and lactation: safety not established; use only if benefit outweighs potential risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mirabegron can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron plasma concentrations. - Antihypertensives (β‑blockers): additive blood‑pressure‑lowering effects. - QT‑prolonging drugs: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may alter urinary symptom control. - Other β3‑agonists: additive bladder‑relaxant effect. - Nitrates: monitor for potential hypotension.